SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-18-007065
Filing Date
2018-08-14
Accepted
2018-08-14 12:37:56
Documents
64
Period of Report
2018-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q gemp-20180630x10q.htm 10-Q 1293006
2 EX-31.1 gemp-20180630ex3118222ab.htm EX-31.1 17976
3 EX-31.2 gemp-20180630ex312daf373.htm EX-31.2 18059
4 EX-32.1 gemp-20180630ex32167c84b.htm EX-32.1 11995
  Complete submission text file 0001558370-18-007065.txt   4535522

Data Files

Seq Description Document Type Size
5 EX-101.INS gemp-20180630.xml EX-101.INS 710984
6 EX-101.SCH gemp-20180630.xsd EX-101.SCH 39973
7 EX-101.CAL gemp-20180630_cal.xml EX-101.CAL 32089
8 EX-101.DEF gemp-20180630_def.xml EX-101.DEF 151871
9 EX-101.LAB gemp-20180630_lab.xml EX-101.LAB 363939
10 EX-101.PRE gemp-20180630_pre.xml EX-101.PRE 284300
Mailing Address 17199 N. LAUREL PARK DRIVE SUITE 401 LIVONIA MI 48152
Business Address 17199 N. LAUREL PARK DRIVE SUITE 401 LIVONIA MI 48152 248-980-6538
Gemphire Therapeutics Inc. (Filer) CIK: 0001638287 (see all company filings)

IRS No.: 472389984 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37809 | Film No.: 181015749
SIC: 2834 Pharmaceutical Preparations
Assistant Director 1